Background: The prognostic impact of tumor bleeding requiring intervention and the correlation with anemia on the survival outcome of cervical cancer radiotherapy is unclear. Methods: One hundred and ninety-six patients requiring hemostatic intervention between January 2006 and March 2014 were retrospectively investigated. The correlation between anemia and bleeding during radiotherapy, the prognostic impact of genital bleeding during radiotherapy and the influence of blood transfusion were estimated. Results: None of the patients had incomplete or prolonged treatment exceeding 1 week due to bleeding. All tumor bleeding could be controlled by gauze packing, and no patients suffered from fatal genital bleeding. Bleeding significantly correlated with progression-free survival (P = 0.015) and overall survival (P = 0.048). Regarding the risk factors of anemia: age (P = 0.043), FIGO stage (P < 0.001), tumor diameter (P < 0.001), and bleeding (P = 0.002) were significant. Multivariate analysis revealed FIGO stage (Odds Ratio: 2.360; 95% CI = 1.202-4.633; P = 0.013), tumor diameter (Odds Ratio: 2.089; 95% CI = 1.048-4.162; P = 0.036) and Bleeding (Odds Ratio: 2.226; 95% CI = 1.052-4.709; P = 0.036) were independent to anemia. Anemia (Hazard Ratio = 1.894; 95% CI = 1.082-3.318; P = 0.025) was only independently correlated with progression free survival, while bleeding (Hazard Ratio = 1.156; 95% CI = 0.556-2.406; P = 0.698) had no independent correlation. Blood transfusion did not improve progression-free survival in patients with anemia or genital bleeding (P = 0.742). Conclusion: We have proved that genital bleeding requiring intervention during cervical cancer radiotherapy is a negligible prognostic factor and is the independent factor for causing anemia. Easily bleeding tumors are potential prognostic markers, which are not effectively treated using existing radiotherapy.
Introduction
Although concurrent chemoradiation has become an established treatment for cervical cancer, the survival outcomes of advanced disease still remain unsatisfactory. Several factors have been found to negatively influence the prognosis of cancer patients undergoing definitive radiotherapy (1) (2) (3) . The adverse prognostic factors which influence definitive radiotherapy in cervical cancer include advanced stages, non-squamous histology, larger tumor size, treatment prolongation, failure to complete radiotherapy (4) . Anemia is also an established prognostic factor for survival not only cervical cancer but also other solid tumors (5-7). Previous reports have described that anemia is a prognostic factor significantly influencing survival; the 5-year disease free-survival rate was 33.2% in hemoglobin level (Hb) ≤ 12.5 g/dl, 57.2% in Hb > 12.5 g/dl in Yalman et al. (8) . However, the proper procedure to alleviate anemia during radiotherapy is still unknown. Anemia is one of the contributing factors for tumor hypoxia, and considered to impair the tumor's response to radiotherapy by reduced tumor oxygenation and resulting in radioresistance (4, 9, 10) . A number of trials demonstrated that tumor hypoxia modification improved local control after the radiotherapy, especially cervical cancer (11) (12) (13) (14) . To date, the impact of tumor hypoxia has not been completely understood in clinical practices.
The cause of anemia following concurrent chemotherapy in cervical cancer remains unclear. The factors that may promote anemia during radiotherapy include bleeding from cervical tumor, treatment that combines radiotherapy with chemotherapy, poor nutritional status, relatively low levels of erythropoietin levels and chronic infection (9) . The possibility of tumor bleeding causing anemia during radiotherapy often necessitates specific interventions in clinical situations. Although there have been examinations regarding the influence of anemia in radiotherapy, there is currently no data regarding the direct influence of genital bleeding on the survival outcome of cervical cancer.
In the present study, the clinical impact of tumor bleeding requiring hemostatic intervention during radiotherapy was investigated in patients with uterine cervical cancer and the correlation to anemia or blood transfusions were also examined.
Materials and methods

Patient population
We retrospectively investigated the clinical database to identify the patients who had planned definitive radiotherapy of uterine cervical cancer as a primary treatment between January 2006 and March 2013. The investigation protocol was approved by the Institutional Review Board (30-20). One patient who lacked complete follow-up data was excluded, and a total of 196 patients who underwent curative radiotherapy were examined. Subjects include 151 patients treated in Kagoshima Medical Center, and 45 patients treated in Kagoshima University Hospital. All patients with invasive cervical cancer from the age of 70 underwent definitive radiotherapy instead of radical hysterectomy, even in the early stage of the disease.
Radiotherapy
A combination of external beam radiation therapy (EBRT) followed by high-dose-rate intracavitary brachytherapy (HDR-ICBT) was administered as definitive radiotherapy. EBRT was delivered 5 days per week to achieve a total dose of 45-59. 4 Gy with AP/PA pelvic portals of 10 MV under guidelines. An HDR-ICBT total dose of Stage I: 29 Gy/5 fractions, Stage II: 23 Gy/4 fractions, and Stages III-IV: 20 Gy/4 fractions were prescribed after midline shielding at point A with a Microselectron HDR-V2 (Nucletron, the Netherlands). Applicators were remotely after-loaded using 192-Iridium, and the PLATO Brachytherapy Planning System version 3.4 (Nucletron, the Netherlands) was administered for HDR-ICBT treatment planning. Conformal radiotherapy or boost EBRT to the primary tumor was planned when high-dose-rate intracavitary brachytherapy could not be administered appropriately. Radiotherapy systems are almost identical in both hospitals, and radiotherapy specialists perform the procedures in each hospital.
Clinical data were collected by completely reviewing inpatient charts and radiotherapy records. Demographic data included age, Eastern Cooperative Oncology Group performance status (PS), International Federation of Gynecology and Obstetrics (FIGO) stage, Histology, tumor diameter, para-aortic lymph node swelling, pelvic lymph node swelling, anemia, bleeding, blood transfusion, concurrent chemotherapy, radiotherapy completion and treatment delay were considered. Patients were classified according to the 1994 International Federation of Gynecology and Obstetrics (FIGO) staging system. Pathological information was collected from pathological reports on cervical biopsies before the initial treatment. The maximum axis of the prominent part on imaging was determined as the tumor diameter. Tumors over 1 cm in diameter were defined as lymph node swelling or distant metastases and were diagnosed according to computed tomography. Anemia was defined as Hemoglobin <10 g/dl. Bleeding during radiotherapy is defined as bleeding from uterine cervical tumors that required hemostatic intervention such as gauze packing, uterine artery embolism or emergency surgical resection. Bleeding which occurred during ICBT was not included in the definition. In our guideline standards, the intervention of gauze packing was initially considered when the active bleeding continued. Blood transfusion was considered with hemoglobin levels <10 g/dl in our standards. The selection of concurrent chemotherapy was decided by the attending stuff's consideration according to age, PS, liver function, kidney function and medical comorbidity. Treatment delay was defined as a treatment break ≥3 days.
Statistical analysis
Inter-group comparisons were performed with the Fischer's exact test. A P value of <0.05 was considered to be significant. Survival curves were calculated using the Kaplan-Meier method, and both progression-free survival (PFS) was compared among groups using the log-rank test. Cox proportional hazards regression analysis and stepwise logistic regression for the multivariate analysis were used to estimate independent variables in multivariate analysis. Baseline variables with P < 0.20 in univariate analysis, and clinically established important factors were included in the multivariate analysis. All statistical analyses were performed on a personal computer with a statistical software package (SPSS for Windows, version 23; SPSS Inc., Chicago, IL, USA). Table 1 shows the characteristics of the enrolled subjects who underwent curative radiotherapy as a primary treatment. The median age was 62.8 years old, median follow up duration was 39.6 months, and FIGO Stage III was the most common (49%) stage. Lymph node swelling was evaluated in detail by computed tomography; only pelvic: 40 patients, only para-aortic: two patients, and pelvic plus para-aortic: 21 patients. All patients underwent complete EBRT, with a total of 29 patients unable to receive complete ICBT. None of the patients had incomplete treatment due to a large amount of bleeding during radiotherapy, or had a treatment prolongation exceeding 1 week. Tumor bleeding in all patients in the Bleeding group could be controlled by gauze packing only, and no patients suffered from fatal genital bleeding during radiotherapy.
Results
Prognostic outcomes between Bleeding group and Non-bleeding group as compared according to the Kaplan-Meier method were examined. Bleeding group significantly showed worse prognosis of the median PFS ( Fig. 1) and OS in all patients (PFS: 23 vs 29 months; Logrank test P = 0.015, OS: 34 vs 42 months; Log-rank test P = 0.048)
The correlation between anemia and bleeding during radiotherapy
The clinical impacts of the relationship between genital bleeding and anemia were examined. 34/49 (69%) patients with bleeding led to anemia, 34/96 (35%) patients with anemia had complicated with bleeding. The median lowest hemoglobin level was 10.0 g/dl (range 4.8-14.0 g/dl), and median time to reach the lowest hemoglobin level was 38.4 days from starting the radiotherapy. Then univariate analyses were performed to identify relationships between anemia during radiotherapy and confounding factors. Of the clinicopathological factors assessed, age (P = 0.043), FIGO stage (P < 0.001), tumor diameter (P < 0.001), and bleeding (P = 0.002) had a significant correlation with anemia (Table 2) . Logistic multivariate analysis revealed that FIGO stage (Odds Ratio: 2.360; 95% CI = 1.202-4.633; P = 0.013), tumor diameter (Odds Ratio: 2.089; 95% CI = 1.048-4.162; P = 0.036) and bleeding (Odds Ratio: 2.226; 95% CI = 1.052-4.709; P = 0.036) were the independent correlated factors for anemia during radiotherapy (Table 3 ).
The prognostic impact of genital bleeding during radiotherapy
The outcome of both PFS and OS by clinicopathological factors were compared according to the Kaplan-Meier method (Table 4) . Univariate analyses were performed to identify risk factors for PFS and OS. The factors of FIGO stage (P = 0.003), tumor diameter (P < 0.001), para-aortic lymph node swelling (P = 0.039), anemia (P < 0.001), blood transfusion (P = 0.038), bleeding (P = 0.015) and treatment delay (P = 0.004) significantly correlated with PFS. The factor of FIGO stage (P = 0.015), histology (P = 0.030), tumor diameter (P = 0.001), anemia (P = 0.002), bleeding (P = 0.048) and radiotherapy completion (P = 0.010) significantly correlated with OS. Figure 2 shows the prognostic outcomes between Bleeding group and Non-bleeding group as compared according to the Kaplan-Meier method and separated by anemia vs non-anemia. Although comparison between the Bleeding group versus Nonbleeding group showed no significant difference in the PFS of the non-anemia disease patients (Log-rank test P = 0.713), Bleeding group tended to have worse prognosis of the median PFS in anemia group (Median survival: 13 vs 19 months; Log-rank test P = 0.093). Cox multivariate analysis was used to clearly identify independent effects on PFS (Table 5 ). The predictive factors of anemia and bleeding have strong correlation and partially confound each other. Accordingly, we statistically examined all indicating variables as 
Correlation between bleeding and blood transfusion
The predictive prognostic factor with blood transfusion could not improve PFS in patients with bleeding (Log-rank test: P = 0.742). Figure 3 shows the prognostic outcomes of PFS between Blood transfusion group and Non-blood transfusion group as compared by anemia levels. Survival benefits were not reached in patients with either hemoglobin < 10 g/dl (Median survival: 13 vs 19 months; Log-rank test P = 0.501) or hemoglobin <8 g/dl (Median survival: 23 vs 10 months; Log-rank test P = 0.495) between blood transfusion and Non-blood transfusion.
Discussion
This retrospective study investigated the survival outcome of patients with genital bleeding which required hemostatic interventions during radiotherapy, and reassessed the clinicopathological variables for causing anemia adding these bleeding patients. The median PFS for the Bleeding group decreased by 6 months compared with the Non-bleeding group. Our analysis showed anemia was the strongest prognostic factor, and bleeding during radiotherapy did not reach to become an independent prognostic factor the same as anemia. Moreover, our research showed FIGO stage and tumor diameter influenced anemia, and genital bleeding also has a direct correlation with anemia in cervical cancer. In clinical situations, there are various amounts and types of bleeding commonly encountered during radiotherapy. Genital bleeding is the most common serious complication in uterine cervical cancer patients. If possible, emergency radical hysterectomy is planned when the aggressive bleeding occurs in the early stage of the disease. In the advanced disease state, invasive treatment, such as gauze packing or uterine artery ligations, are often used until the radiotherapy is effective (15) . Massive genital bleeding often occurs even during radiotherapy, and blood transfusions are necessary for severe anemia. However, only limited information is available regarding the significance of genital bleeding associated with definitive radiotherapy treatment in cervical cancer (9, 16) . Previous studies have reported that the factors that influenced survival rates in radiotherapy were an advanced stage, a large tumor size, non-squamous cell carcinoma, treatment prolongation, failure to complete radiotherapy, a lack of concurrent chemoradiation and anemia (4, 8, 17) . Acute toxicity of Grade 3-4 anemia during concurrent chemoradiation was observed in 14% of cervical cancer patients (18) . Several reports have demonstrated that during radiotherapy, hemoglobin levels are correlated with survival outcome (1, 5) . Dunst et al. revealed that the combination of hemoglobin ≥11 g/dl before treatment and 19.8 Gy of EBRT provided the best prognosis for patients (5) . Patients with anemia at 19.8 Gy had a significantly worse prognosis, regardless of whether or not they had pretreatment anemia. Multivariate analysis showed that long-term follow-up of CCRT incorporating HDR-ICBT with a lower cumulative radiotherapy setting, tumor size and pretreatment hemoglobin level were significant factors for survival in advanced uterine cervical cancer (1) . However, there is no detailed information available on the cause of anemia compared with non-anemic patients. Our data indicated that FIGO stage and tumor diameter were the most influential factor for anemia, and bleeding also caused anemia independently during radiotherapy in cervical cancer. We adopted the cut-off hemoglobin level 10 g/dl for analyses, because the preanalysis indicated that levels of hemoglobin over the 10 g/dl of hemoglobin levels in our cohort was good prognosis. In our cohort, only 26% of patients were higher than hemoglobin 11 g/dl, which was fewer patients than other articles.
Previous reports have described the association between anemia and poor tumor oxygenation (5, 16, 19) . Dunst et al. (20) investigated normal tissue oxygenation and tumor oxygenation in 133 patients with head-and-neck cancers. Anemia had no impact on normal tissue oxygenation but was strongly associated with tumor hypoxia. This process leads to increased vascularization. Although the fact that normal tissue compensated for mild-to-moderate anemia by increasing tissue perfusion, compensatory mechanisms are reduced in tumors due to atypical vascular networks (5) . Tumor hypoxia was correlated with serum levels of angiogenic cytokines in some cancers. Mattern et al. (21) reported that expression of vascular endothelial growth factor (VEGF) was increased in hypoxic rectal cancer patients, and higher serum VEGF levels were the only important factor for survival in anemic cancer patients. An angiogenic inhibitor, bevacizumab, is a DNA-derived monoclonal antibody that selectively binds to and inhibits activity of human VEGF to reduce microvascular growth and inhibit disease progression, and higher serum VEGF patients are possible candidates for examining antiangiogenic medicines. In ovarian cancer, it was evident that retreatment serum VEGF was a predictive value for the efficacy of bevacizumab (22) . On the other hand, although it is evident that VEGF is a prognostic factor for the outcome of radiotherapy in advanced cervical cancer (23) , there is no correlation between hypoxia and angiogenesis and levels of angiogenic proteins do not have a role in assessing hypoxia in Catharine's research (24) .
Several studies have reported that appropriate radiotherapy performance has prognostic significance for cervical cancer patients treated with curative intent radiotherapy (2) . The present study shows that no patients were without complete radiotherapy or experienced treatment delay due to genital bleeding during radiotherapy. Therefore, genital bleeding may not influence survival outcomes due to completion of radiotherapy. The direct influence of genital bleeding on the survival outcome and correlation with anemia of cervical cancer radiotherapy have not been estimated. The factors that influence genital bleeding during radiotherapy for anemia are not yet understood. Our findings suggest that the anemia is more correlate with stages, tumor size and tumor bleeding than induced by treatments such as myelosuppression due to higher doses of radiotherapy and dense dosage of concurrent chemotherapy. Easily bleeding tumors may often respond poorly to radiotherapy, and continue to persistently bleed. This issue may indicate that easily bleeding genital tumors indirectly influence the prognosis. Thus, regardless of blood transfusion for improving tumor oxygenation, the tumor did not always improve as expected. Blood transfusions could not show significant survival benefits even if considered a factor of bleeding in our research. Blood transfusion for severe anemia Figure 3 . Progression-free survival of the anemia patients in the blood transfusion group and the Non-blood transfusion group by anemia levels.
(hemoglobin <10g/dl) also tended to improve the prognosis but was insignificant. The limitation of estimating the efficacy of blood transfusion for anemia and the recording of hemoglobin levels after the blood transfusion could not always be monitored in our cohort. Maintaining normal hemoglobin levels requires frequent examination. The patients in need of blood transfusions, such as those complicated with bleeding, were potentially high-grade malignancy populations so more investigation is needed to confirm the significance of blood transfusions.
In conclusion, the present study shows that while not reaching and independent factor for PFS, genital bleeding during radiotherapy may a critical prognostic factor and is indirectly associated with a poor prognosis in cervical cancer by causing anemia. Factors that directly influenced prognosis, such as a large amount of fatal bleeding, bleeding-induced incomplete treatments were not present in this study. Easily bleeding tumors is a potential prognostic marker, which is not effectively treated using existing radiotherapy. Examination of the efficacy of newly developed antiangiogenic therapies, such as bevacizumab, is warranted in this group.
